Intelligence Feed event · Policy · 2026-08-30

    Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026

    Question

    Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026

    Direct answer

    Cytokinetics presented detailed Phase 3 trial findings for its cardiac myosin inhibitor aficamten (MYQORZO) at the European Society of Cardiology (ESC) Congress 2026 in late-breaking clinical trial sessions. Results from the ACACIA-HCM trial demonstrated statistically significant improvements in cardiac structural remodeling and diastolic function beyond baseline exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-30
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026”, revision 1, evidence through 2026-08-30. https://marketontology.com/market-events/2026-08-30/cytokinetics-presents-aficamten-phase-3-data-at-esc-congress-2026-4705d4

    POLICY
    Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026
    Cytokinetics presented detailed Phase 3 trial findings for its cardiac myosin inhibitor aficamten (MYQORZO) at the European Society of Cardiology (ESC) Congress 2026 in late-breaking clinical trial sessions. Results from the ACACIA-HCM trial demonstrated statistically significant improvements in cardiac structural remodeling and diastolic function beyond baseline exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy.
    CYTK
    Impact
    73
    AUG 30
    SIG
    90%
    CYTK
    Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026
    Cytokinetics presented detailed Phase 3 trial findings for its cardiac myosin inhibitor aficamten (MYQORZO) at the European Society of Cardiology (ESC) Congress 2026 in late-breaking clinical trial sessions. Results from the ACACIA-HCM trial demonstrated statistically significant improvements in cardiac structural remodeling and diastolic function beyond baseline exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy.
    → Positive Phase 3 cardiovascular structural endpoint data strengthens regulatory approval probability for aficamten, de-risking CYTK biopharma revenue pipeline.
    Impact
    Cytokinetics presented detailed Phase 3 trial findings for its cardiac myosin inhibitor aficamten (MYQORZO) at the European Society of Cardiology (ESC) Congress 2026 in late-breaking clinical trial sessions. Results from the ACACIA-HCM trial demonstrated statistically significant improvements in cardiac structural remodeling and diastolic function beyond baseline exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy.
    Affected
    CYTK
    Transmission
    Positive Phase 3 cardiovascular structural endpoint data strengthens regulatory approval probability for aficamten, de-risking CYTK biopharma revenue pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CYTKregulatory approval de-risking and addressable market expansion in non-obstructive HCMUp1-4wACACIA-HCM data showed aficamten improved cardiac structure and diastolic function at ESC Congress 2026.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month